S0758
Sulfaphenazole
≥98%, CYP2C9 inhibitor, powder
Synonym(s):
4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C15H14N4O2S
CAS Number:
Molecular Weight:
314.36
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352204
EC Number:
208-384-3
MDL number:
Product Name
Sulfaphenazole, ≥98%
Quality Level
assay
≥98%
form
powder
solubility
ethanol: 25 mg/mL, clear, colorless to yellow
storage temp.
2-8°C
SMILES string
Nc1ccc(cc1)S(=O)(=O)Nc2ccnn2-c3ccccc3
InChI
1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2
InChI key
QWCJHSGMANYXCW-UHFFFAOYSA-N
Gene Information
human ... CYP2C18(1562), CYP2C19(1557), CYP2C9(1559)
Application
Sulfaphenazole has been used as a positive control to inhibit cytochrome P450 2C9 (cyp2c9) to quantify Rhodiola rosea inhibition. It has also been used as cytochrome P450 2C9 (cyp2c9) inhibitor in endothelial cells and microsomal preparations.
Biochem/physiol Actions
Antibacterial. Specific inhibitor of CYP2C9. Blocks pro-inflammatory and atherogenic effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Specific inhibitor of CYP2C9. Blocks pro-inflammatory and atherogenic effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Inhibits bradykinin-induced tPA release.
Still not finding the right product?
Explore all of our products under Sulfaphenazole
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform
Moraes CB, et al.
SLAS discovery, 24(3), 346-361 (2019)
Zhiping Jin et al.
Basic & clinical pharmacology & toxicology, 130(5), 592-605 (2022-03-16)
Anlotinib is a small molecule of novel tyrosine kinase inhibitor initially approved to treat non-small cell lung cancer in China. Drug-drug interaction (DDI) is an extrinsic factor important for the appropriate use of anlotinib in clinical practice. In vitro experiments
Vienna E Brunt et al.
The Journal of physiology, 590(15), 3523-3534 (2012-06-08)
While it is accepted that NO is responsible for ∼60% of the plateau in cutaneous thermal hyperaemia, a large portion of the response remains unknown. We sought to determine whether the remaining ∼40% could be attributed to EDHF-mediated activation of